Freezing of Gait as a Complication of Pallidal Deep Brain Stimulation in DYT- KMT2B Patients with Evidence of Striatonigral Degeneration
Authors:
Laura Cif,
Diane Demailly,
Xavier Vasques,
Delphine de Verbizier,
Philippe Coubes,
Kathleen Gorman,
Manju A Kurian
Abstract:
Background: Mutations in KMT2B are a recognized cause of early-onset complex dystonia, with deep brain stimulation (DBS) of the internal globus pallidus (GPi-DBS) being an effective treatment. However, gait impairment, particularly freezing of gait (FOG), remains a significant challenge in DYT-KMT2B patients post-DBS. Objectives: To characterize the emergence of FOG in DYT-KMT2B patients treated w…
▽ More
Background: Mutations in KMT2B are a recognized cause of early-onset complex dystonia, with deep brain stimulation (DBS) of the internal globus pallidus (GPi-DBS) being an effective treatment. However, gait impairment, particularly freezing of gait (FOG), remains a significant challenge in DYT-KMT2B patients post-DBS. Objectives: To characterize the emergence of FOG in DYT-KMT2B patients treated with GPi-DBS and explore potential underlying mechanisms, including striatonigral degeneration. Methods: Five patients (four females) with KMT2B-related dystonia and protein-truncating variants (PTVs) were retrospectively analyzed. Clinical progression, response to GPi-DBS, and the presence of FOG were documented. Dopaminergic function was assessed using DaTscan (SPECT for ^123I-ioflupane) in four patients. Results: FOG developed in all patients, with onset ranging from 1 to 15.5 years post-DBS. DaTscan abnormalities, indicative of bilateral striatal dopaminergic denervation, were observed in four cases. Prior to DBS, all patients exhibited dystonia unresponsive to L-dopa, and post-DBS, FOG remained refractory to dopaminergic treatment in most cases. Despite initial improvements in gait post-DBS, only one patient maintained independent ambulation at the last follow-up. Conclusions: FOG is an emerging complication in DYT-KMT2B patients with PTVs undergoing GPi-DBS, potentially linked to underlying striatonigral degeneration. The findings suggest a need for long-term motor surveillance and consideration of alternative therapeutic strategies, including dopaminergic trials, in this patient population. Further studies are required to elucidate the precise mechanisms driving DBS-related hypokinetic gait disturbances in DYT-KMT2B dystonia.
△ Less
Submitted 19 February, 2025;
originally announced February 2025.
KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation
Authors:
L Cif,
D Demailly,
JP Lin,
KE Barwick,
M Sa,
L Abela,
S Malhotra,
WK Chong,
D Steel,
A Sanchis-Juan,
A Ngoh,
N Trump,
E Meyer,
X Vasques,
J Rankin,
MW Allain,
CD Applegate,
S Attaripour Isfahani,
J Baleine,
B Balint,
JA Bassetti,
EL Baple,
KP Bhatia,
C Blanchet,
L Burglen
, et al. (90 additional authors not shown)
Abstract:
Heterozygous mutations in KMT2B are associated with an early-onset, progressive, and often complex dystonia (DYT28). Key characteristics of typical disease include focal motor features at disease presentation, evolving through a caudocranial pattern into generalized dystonia, with prominent oromandibular, laryngeal, and cervical involvement. Although KMT2B-related disease is emerging as one of the…
▽ More
Heterozygous mutations in KMT2B are associated with an early-onset, progressive, and often complex dystonia (DYT28). Key characteristics of typical disease include focal motor features at disease presentation, evolving through a caudocranial pattern into generalized dystonia, with prominent oromandibular, laryngeal, and cervical involvement. Although KMT2B-related disease is emerging as one of the most common causes of early-onset genetic dystonia, much remains to be understood about the full spectrum of the disease. We describe a cohort of 53 patients with KMT2B mutations, with detailed delineation of their clinical phenotype and molecular genetic features. We report new disease presentations, including atypical patterns of dystonia evolution and a subgroup of patients with a non-dystonic neurodevelopmental phenotype. In addition to the previously reported systemic features, our study has identified co-morbidities, including the risk of status dystonicus, intrauterine growth retardation, and endocrinopathies. Analysis of this study cohort (n = 53) in tandem with published cases (n = 80) revealed that patients with chromosomal deletions and protein-truncating variants had a significantly higher burden of systemic disease (with earlier onset of dystonia) than those with missense variants. Eighteen individuals had detailed longitudinal data available after insertion of deep brain stimulation for medically refractory dystonia. Median age at deep brain stimulation was 11.5 years (range: 4.5 to 37.0 years). Follow-up after deep brain stimulation ranged from 0.25 to 22 years. Significant improvement of motor function and disability (as assessed by the Burke-Fahn-Marsden Dystonia Rating Scales, BFMDRS-M and BFMDRS-D) was evident at 6 months, 1 year, and last follow-up (motor, P = 0.001, P = 0.004, and P = 0.012; disability, P = 0.009, P = 0.002, and P = 0.012).
△ Less
Submitted 10 February, 2025;
originally announced February 2025.
